NervGen Pharma (NGEN) appointed Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as Senior Vice President, SVP, Patient Advocacy and Clinical Affairs. Most recently, Ruff served as Chief Regulatory Affairs Officer and SVP, Head of Quality Assurance at Stoke Therapeutics (STOK). Previously, McSherry co-founded Casimir
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGEN:
- NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program
- NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal
- NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase
- NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase
- Nanogen names Adam Rogers as president and CEO, effective immediately